The fight against coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 infection is
still raging. However, the pathophysiology of acute and post-acute manifestations of COVID …

Abstract Coronavirus disease 2019 (COVID-19) predisposes patients to thrombotic and
thromboembolic events, owing to excessive inflammation, endothelial cell activation and …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Antithrombotic agents reduce risk of thromboembolism in severely ill patients. Patients with
coronavirus disease 2019 (COVID‐19) may realize additional benefits from heparins …

Abstract Background: COVID-19–related acute illness is associated with an increased risk of
venous thromboembolism (VTE). Objective: These evidence-based guidelines from the …

Objective To provide guidance on the management of Multisystem Inflammatory Syndrome
in Children (MIS‐C), a condition characterized by fever, inflammation, and multiorgan …

Background Evidence on post-acute sequelae of SARS-CoV-2 (PASC) has shown
inconsistent findings. This study aimed to generate coherent evidence on the post-acute …

Heparin has been used extensively as an antithrombotic and anticoagulant for close to 100
years. This anticoagulant activity is attributed mainly to the pentasaccharide sequence …

В конце 2019 г. в Китайской Народной Республике (КНР) произошла вспышка новой
коронавирусной инфекции с эпицентром в городе Ухань (провинция Хубэй). Всемирная …

Background The primary manifestation of coronavirus disease 2019 (COVID‐19) is
respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and …